Back to results
US 2015/0104881 A1Published application
Sglt2 as biomarker for diagnosing chronic kidney disease and monitoring the disease status after treatment
AssigneeNational Defense Medical Center
InventorsAnn CHEN, Shuk-Man KA
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for diagnosis of a chronic kidney disease in a subject by detecting the expression level of a sodium-glucose linked transporter 2 (SGLT2) protein in urine samples. A method for monitoring progression of a chronic kidney disease in a patient is also provided.
Claims13
A method for diagnosing a chronic kidney disease in a subject, comprising
- (a) obtaining a urine sample from the subject;
- (b) determining a level of a sodium-glucose linked transporter 2 (SGLT2) protein in the urine sample;
- and
- (c) identifying the subject as having or at risk for the chronic kidney disease, if the level of the SGLT2 protein in the urine sample is increased relative to the level of the SGLT2 protein in urine from a control.
1 more element
A method for monitoring progression of a chronic kidney disease (CKD), comprising
- (a) providing a first urine sample from a patient with CKD at a first time point;
- (b) providing a second urine sample from the patient at a second time point;
- which is later than the first time point;
- (c) measuring levels of a sodium-glucose linked transporter 2 (SGLT2) protein in the first and second urine samples by an immunoassay;
- and
- (d) determining progression of the chronic kidney disease in the patient based on the levels of the SGLT2 protein in the first and second urine samples, wherein an increased level of the SGLT2 protein in the second urine sample relative to that in the first urine sample is indicative of progression of the chronic kidney disease in the patient.
3 more elements
Dependencies are inferred from the claim text.